Aeon Biopharma Inc AEON

$0.28 -0.01 (-3.79%)

Valuation

Market cap
14,466,000
Revenue TTM
$0
Net income TTM
$-39,220,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,233,600
Avg volume
9,478,750
Day's range
$0.26 – $0.30
Shares out
49,883,000
Stochastic %K
22%
Beta
0.69
Analysts
Strong Sell
Price target
$1.77

Price

Company profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-tra...

Show more

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Industry
Biotechnology
Sector
Healthcare
Phone
949 354 6499
Website
https://www.aeonbiopharma.com
Address
5 Park Plaza, Suite 1750, Irvine, United States

Latest news

Stocktwits

14kmaker Oct 2, 8:22 PM
$AEON i’m right there with you TW I’m very bullish on this stock, but the numbers are the numbers they’re gonna have to raise money before they start playing these FDA games. I think the market knows this and the market also possibly sees a reverse split.
1 replies
TW_Research Oct 2, 7:21 PM
$AEON Disappointed doesn't begin to describe my thoughts on this stock. The company likely just saved $30M and almost a year by not needing a comparative study. The molecule is so well studied that they can innundate the FDA with data. Approval seems highly likely and this will take a ton of share due to better economics. I was so excited to buy it here on Wednesday. Thought it would never trade here again. I guess the moral to the story is that all micro-cap biotechs are trading vehicles not investments?!? Dang...
0 replies
CyrusTrade Oct 2, 2:58 PM
$AEON back to ATL
0 replies
DayTrade_4Life Oct 2, 2:57 AM
💵Some Stocks to Watch for 2 Oct: ​AMOD SMX NIVF SORA SSM $VEEA $SDEV $AEON 🏆Below are Results form today and Last Month. 👉See Profile to Join Us.
0 replies
Knowhyners Oct 1, 7:23 PM
$AEON 3 cents on a 100% new valuation,
1 replies
investinsince07 Oct 1, 5:14 PM
$AEON this is true. Just released. Let it cook.
0 replies
Nav_Uta Oct 1, 1:17 PM
$AEON Lake Street raised the firm’s on Biopharma (AEON) to $2 from $1 and keeps a Buy rating on the shares after the company announced the outcome of its Type 2b meeting with FDA.
0 replies
TW_Research Oct 1, 12:58 PM
$AEON The $.32 warrants are not cashless @Tony2341 My guess is stock trades through there soon and they get exercised. Funds them for a nice while. The value here, if they don’t need a comparative study is excellent.
0 replies